Trial Profile
COR111096, A Randomized, Double-Blind, Active-Controlled, Parallel Group, Multicenter Study Comparing The Proportion of Subjects With Stage 1 or 2 Essential Hypertension Who Achieve Target Blood Pressure While Receiving Either COREG CR [carvedilol] + Lisinopril or Lisinopril Monotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Aug 2023
Price :
$35
*
At a glance
- Drugs Carvedilol (Primary) ; Lisinopril
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 04 Sep 2009 Actual patient numbers amended from (432) to (348) as reported by ClinicalTrials.gov.
- 04 Sep 2009 Actual end date (Mar 2008) added as reported by ClinicalTrials.gov.
- 05 Aug 2009 Actual patient number (432) added as reported by ClinicalTrials.gov.